Centrus Energy shares climbed 6.0% in early trading, moving from a pre-session level near $177 to intraday highs of $204.98 after Stifel reiterated a Buy rating on the stock while lowering its 12-month price objective to $216 from $246. The maintained positive stance from Stifel, even with a reduced target, coincided with a notable rebound given the stock's depressed starting point relative to analyst targets.
Stifel's published note framed Centrus's solid second-quarter 2026 operating performance as the basis for continued optimism. The company reported revenue of $176.1 million for the quarter, a 14% increase compared with the prior year. Stifel highlighted that Centrus's commercial backlog expanded by about $600 million sequentially to reach $4.5 billion, and that financing contingencies had been removed from more than $3 billion of commercial contracts for low-enriched uranium (LEU) and high-assay low-enriched uranium (HALEU).
The removal of these financing contingencies was characterized in the note as a material de-risking of the company's revenue pipeline. Stifel indicated that, despite the potential headwinds from the Department of Energy's budget outlook, Centrus's long-term discounted cash flow work continues to support a Buy recommendation.
Other sell-side activity has been generally constructive. Barclays recently initiated coverage with an Equal Weight rating and set a $207 target, while UBS increased its target to $185 from $170 on the back of improved margin and EBITDA assumptions. These analyst actions, together with Stifel's maintained Buy, left multiple price targets above the stock's trading level heading into the session.
The broader U.S. equity market provided little directional lift on the day, with the S&P 500 rising only 0.03%, the Dow Jones essentially flat, and the Nasdaq slightly lower. That muted market backdrop implies that LEU's outperformance was driven primarily by company-specific news and analyst reassessments rather than a generalized market rally.
Investors appeared to weigh Centrus's immediate budget-related uncertainty against its stretched-out backlog and explicit government business. The company's reported $4.5 billion backlog, which the note said extends through 2040, alongside an active $900 million DOE enrichment contract, were cited as central to the improved risk-reward calculus that supported the stock's intraday recovery.
In sum, the combination of a sustained analyst Buy call from Stifel—albeit with a lower price target—recent quarterly growth in revenue, a significantly increased and de-risked commercial backlog, and visible government contract revenue together underpinned the rally in Centrus shares during morning trading.